NEWS AND EVENTS
NEWS AND EVENTS
Sanifit announces completion of enrollment in CaLIPSO – its Phase 2b Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis
Palma, Spain and San Diego, USA, August 6th, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the completion of enrollment of its Phase 2b CaLIPSO clinical trial investigating Sanifit’s lead candidate SNF472, for the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients on haemodialysis (HD). […]
Sanifit to present at the 2018 European Biotech Investor Day in New York City
Palma, Spain and San Diego, USA, July 17, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, will present at the European Biotech Investor Day in NYC, organized by Solebury Trout, Goodwin LLC and Nasdaq. Sanifit will present at 3.00 PM on Thursday, July 19. Dr Joan Perelló, […]
Sanifit Presents Results from Phase 2 Clinical Trial of SNF472 at ERA-EDTA Congress
Palma, Spain and San Diego, USA 25th May 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, announced that the results of its Phase 2 clinical trial of SNF472 were presented during an oral session earlier today at the 55th ERA-EDTA Congress taking place in Copenhagen, Denmark. The presentation […]
Sanifit is delighted to Announce that Dr Joan Perelló has been granted the “CEO Today Europe Award”
The international magazine CEO Today has published a list with the 100 Europe’s most talented Chief Executive Officers whose commitment to excellence and achievements are worth cheering for. Every year CEO Today Magazine identifies and honors the most progressive, forward-thinking and ambitious company leaders in todays’ business. The CEO Today team collate votes and in-depth […]
Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis
Palma, Spain and San Diego, USA March 06, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, announced today the completion of its Phase II clinical trial of SNF472, its lead candidate for the treatment of the orphan disease calciphylaxis (calcific uraemic arteriolopathy, CUA), with both primary and secondary […]
Latest News
UPCOMING EVENTS
11th-14th January – JPMorgan, San Francisco, USA
4th – 6th April – BIO Europe Spring, Stockholm, Sweden
27th April – 1st May – NKF Clinical Meeting, Boston, USA
21st – 24th May – ERA – EDTA, VIenna, Austria
6th – 9th June – BIO, San Francisco, USA
7th – 9th November – BIO Europe, Cologne, Germany
15th – 20th November – ASN Kidney Week, Chicago, USA